TDB-DST signs agreement with Peptris for ₹86 crore RDI support to accelerate AI-driven drug discovery and development

1. At a Glance

• TDB (under DST) has signed an agreement to give ₹86 crore to Peptris Technologies Pvt Ltd, Bengaluru from the Research Development and Innovation (RDI) Fund, for an AI-led drug discovery project. [1]
• The project is VIGOR: Advancing AI-Discovered Molecules from Bench to Clinic. It aims to move four drug candidates from TRL-4 to TRL-6. [1]
• The money is given as Optionally Convertible Debt (OCD), a hybrid of loan and equity. It is not a grant. [1]
• Why it matters for UPSC: this is one of the early uses of the ₹1 lakh crore RDI Scheme [2]. It links AI, biotech and pharma, and shows how the state finances risky private R&D (GS-III S&T and Economy).

2. Why in the News

• On 12 October 2026, PIB announced that TDB-DST had signed the RDI Fund agreement with Peptris for the VIGOR programme. [1]

3. Background & Evolution

• 1995: The Technology Development Board Act, 1995 (Act No. 44) was enacted on 16 December 1995. Its purpose is to finance industrial concerns that develop indigenous technology or adapt imported technology for wider domestic use. [4]
• 1996: TDB was set up as a statutory body under DST. Search snippets give its start as 1 September 1996 and the Act's enforcement as 1 November 1996; check these dates. [3][4]
• The Act creates a fund: the Fund for Technology Development and Application, run by TDB. [4]
• 1 July 2025: The Union Cabinet approved the RDI Scheme with a corpus of ₹1 lakh crore. [2]
• 12 October 2026: TDB and Peptris signed the VIGOR agreement under the RDI Fund. [1]

4. Core Static Facts

Item	Fact
Funding body	Technology Development Board (TDB), Department of Science & Technology [1]
Legal basis of TDB	TDB Act, 1995 (Act No. 44 of 1995) [4]
TDB's usual forms of support	Equity, soft loans, grants [3]
Beneficiary	Peptris Technologies Pvt Ltd, Bengaluru, Karnataka [1]
Fund	Research Development and Innovation (RDI) Fund [1]
RDI Scheme corpus	₹1 lakh crore; Cabinet approval on 1 July 2025 [2]
Project name	VIGOR: Advancing AI-Discovered Molecules from Bench to Clinic [1]
Total project cost	₹172 crore [1]
TDB support	₹86 crore, which is 50% of the project cost [1]
Instrument	Optionally Convertible Debt (OCD) [1]
Duration	3 years [1]
TRL target	TRL-4 to TRL-6 [1]
Work covered	Advanced preclinical and IND-enabling studies, formulation development, preparation for and start of clinical trials [1]
Execution model	Peptris's own AI platform plus global CRO networks [1]
TDB Secretary quoted	Sh. Rajesh Kumar Pathak [1]

The four drug candidates [1]

Candidate	Therapeutic area
PEPR111	Neuromuscular disorders and oncology
PEPRX101	Alopecia
PEPR202	Neuropathy
PEPR112	DMD (usually expanded as Duchenne Muscular Dystrophy; the release uses only "DMD")

Key terms (concept)

• TRL (Technology Readiness Level): a 1–9 scale of how mature a technology is. TRL-4 is validation in a lab. TRL-6 is a prototype shown in a relevant environment.
• IND (Investigational New Drug): the regulatory filing that must be approved before human trials can begin. "IND-enabling studies" are the preclinical toxicology, pharmacology and manufacturing work needed for that filing.
• CRO (Contract Research Organisation): an outside firm hired to run preclinical or clinical studies.
• OCD (Optionally Convertible Debt): a loan that the lender can choose to convert into equity. The state can share in the upside if the project succeeds, and the money is returned if it does not.

5. Multi-Dimensional Analysis

Scientific / Technological

• AI helps find promising molecules, study disease mechanisms and speed up the search for therapies. [1]
• The hard step is turning computational hits into real drug candidates. That needs experimental validation, preclinical studies and clinical development. VIGOR is aimed at exactly this step. [1]
• The programme pairs AI-based discovery with established drug-development methods and global CROs. [1]

Economic

• Financing is shared 50:50 (₹86 crore of ₹172 crore), so private capital stays at risk alongside public money. [1]
• Using OCD instead of a grant means the money can come back to the fund or turn into a stake. This fits TDB's mandate of equity, loan and grant support. [1][3]
• The RDI Scheme's ₹1 lakh crore corpus is meant to fill the funding gap for later-stage, high-TRL private R&D. [2]

Social / Health

• The programme targets diseases with significant unmet medical need, where good treatments are limited. [1]
• DMD and some neuromuscular disorders fall in the rare-disease space. Domestic development of drugs for them could help access and affordability (concept; not in the release).

Governance / Ethical

• Progress is "subject to the relevant scientific and regulatory requirements." AI-discovered molecules still have to clear the full preclinical and IND process. [1]
• (concept) Open questions include whether AI models are transparent, who owns the data, how IP is shared under OCD, and how success is measured against TRL milestones.

Administrative

• The fund is administered by a long-standing statutory financier (TDB, created under the 1995 Act), not by a new body. [1][4]

6. Recent Developments (last 12–18 months)

• 1 July 2025: Cabinet approved the RDI Scheme with a ₹1 lakh crore corpus. [2]
• 12 October 2026: TDB-DST signed the ₹86 crore OCD agreement with Peptris for VIGOR. [1]
• (Other RDI Fund calls and TDB project approvals were reported only by sources outside the whitelist, so they are not included.)

7. Prelims Hooks

• TDB is a statutory body under the Department of Science & Technology. It is not under DBT or MeitY. [1][3]
• TDB was created under the Technology Development Board Act, 1995 (Act No. 44 of 1995). [4]
• TDB Act enacted on 16 December 1995. [4]
• TDB gives equity, soft loans and grants. [3]
• The TDB Act provides for the Fund for Technology Development and Application. [4]
• The RDI Scheme has a corpus of ₹1 lakh crore and was approved by Cabinet on 1 July 2025. [2]
• The VIGOR project costs ₹172 crore in total, with ₹86 crore from TDB under the RDI Fund. [1]
• Peptris's support comes as Optionally Convertible Debt. [1]
• VIGOR takes four AI-discovered candidates from TRL-4 to TRL-6 over three years. [1]
• Peptris Technologies is based in Bengaluru, Karnataka. [1]
• PEPRX101 is for alopecia; PEPR202 for neuropathy; PEPR112 for DMD; PEPR111 for neuromuscular disorders and oncology. [1]
• VIGOR stands for "Advancing AI-Discovered Molecules from Bench to Clinic." [1]

8. Why the State Lends Here Instead of Leaving It to the Market

• Indian companies pay for far too little of the country's research
• India's GERD (Gross Expenditure on R&D, meaning all money spent on research in the country) was only 0.64% of GDP in 2020-21. It was 0.66% in both 2018-19 and 2019-20 [7].
• The government pays for about 64% of this. Private companies pay for only about 36% [8].
• In China, Japan, Korea and the USA, companies pay for more than 70% [8].

• So the problem is not only a small total. Private money is missing.

• The stage VIGOR funds is the one where private money stops most often

• TRL-4 to TRL-6 comes after the lab idea and before human trials. It is costly, it takes years, and the product still earns nothing.
• Banks lend against collateral (property or assets they can take back). A young AI-drug firm has very little of that.

• The RDI Scheme says it will judge a project by its technology, its TRL and its market potential, not by collateral alone. It only funds projects at TRL-4 and above [5].

• The scheme is built to lend, not to give

• The RDI Scheme gives no grants. It supports firms mainly through long-term, low-interest loans, equity and equity-linked instruments [6].
• So the OCD to Peptris is not a special case. It is the normal design of the scheme.

9. What Happens to the Loan If the Drugs Fail

• The note says the money "is returned if the project fails". That is the hopeful case.
• OCD is still debt. A company has to repay it from its own income.
• If all four candidates fail before reaching patients, Peptris may have no product to sell and no revenue to repay from (concept).

• In that case the "loan" works like a grant that has to be written off.

• Putting four molecules in one project spreads the risk, but only partly

• VIGOR backs four candidates for four different conditions [1]. One failure does not end the project.

• But all four come from the same AI platform [1]. If the platform's predictions are weak, the four candidates may fail for the same reason (concept).

• What the release does not tell us

• The release gives no interest rate, no conversion price for the equity option, and no repayment schedule [1].
• Without these, nobody outside can judge whether the public gets a fair share of the upside if the drugs succeed.

10. ₹86 Crore Against ₹1 Lakh Crore: Is the Money Actually Moving?

• The corpus is huge on paper but small in practice so far
• The RDI Scheme has ₹1 lakh crore spread over six years [5]. That is roughly ₹16,700 crore a year on average.
• The Budget for FY 2025-26 gave ₹20,000 crore [5].

• But only two fund managers, TDB and BIRAC, were sanctioned ₹1,000 crore each. Only ₹500 crore had reached TDB by March 2026 [6].

• Why the money moves slowly

• The RDI Fund does not invest in companies directly. It passes money to second-level fund managers (TDB, BIRAC, AIFs, NBFCs, DFIs), and they choose the projects [5].
• Each extra layer adds its own checks and its own selection round before any firm is paid.
• So deals like VIGOR are the real test: the scheme's success will show in how many such deals happen, not in the size of the corpus.

11. Public Money, Private Molecules: Who Gets the Benefit?

• The release attaches no price or access conditions for India
• Half of the project cost is public money [1]. But the release says nothing about affordable pricing in India, about India getting the drugs first, or about keeping the IP (intellectual property, meaning ownership of the invention) in India [1].

• The clinical and preclinical work runs through global CRO networks [1]. So part of the spending, and the skills it builds, may go abroad.

• The choice of diseases is mixed

• PEPR112 targets DMD, a rare disease where Indian patients have very few treatments [1].

• PEPRX101 targets alopecia (hair loss) [1]. That is a large global market, but a weaker public-health case for public money.

• What TDB should do

• TDB should publish access and pricing terms for rare-disease candidates like PEPR112 in future RDI deals.
• These terms should link to the National Policy for Rare Diseases, 2021, so that public money buys some public return, not only a financial one.
• WHO's guidance on AI in health names inclusiveness and equity as a core principle. This means AI tools should help people who are underserved, not only big markets [9].

12. The Rules for AI-Discovered Drugs Have Not Caught Up

• No country has a full rulebook yet
• WHO says there is still no comprehensive international guidance on using AI in health. It also says most countries have no specific laws for it [9].

• India's drug approvals run under the New Drugs and Clinical Trials Rules, 2019, through CDSCO. These rules do not separately deal with how an AI model chose a molecule (concept).

• Why this matters for VIGOR

• The molecule itself will be tested like any other drug. That part is safe [1].
• The weak spot is the AI part. If the IND dossier (the application to start human trials) relies on AI predictions, the regulator needs a way to check how the model was trained and on whose data.

• Without clear rules, every company gets judged case by case. That slows approvals and makes investors less certain.

• What CDSCO and DST should do

• CDSCO should issue guidance on how AI-generated evidence can be used in IND filings.
• It should be based on WHO's principles of transparency (being able to see how the model works) and accountability (a named person answers for its errors) [9].

13. Should Taxpayers Back a Private Firm's Drug Bets at All?

• The strongest case against
• Peptris is a private company. If its drugs succeed, private shareholders gain the most.
• Most drug candidates fail (concept). Public money at this stage may often be lost.

• Critics would say the same ₹86 crore could fund public labs or rare-disease treatment directly.

• The honest answer

• The critics are right that the public return is unclear. The release gives no access terms and no repayment details [1].
• But the state is not the only one taking the risk. Peptris and its investors pay the other ₹86 crore [1].
• Using OCD instead of a grant means the state can share in success through equity, which a grant never allows [1].

• The deeper reason is the gap itself. With companies paying for only about 36% of India's research [8], waiting for the market alone has not worked.

• Verdict: public support is justified, but only if it comes with published terms. Each deal should state the interest rate, the conversion terms and the access conditions.

14. Anchors for Answers

• Data: India's GERD was 0.64% of GDP in 2020-21, with no rise for several years [7]; government pays for about 64% of GERD and the private sector about 36% [8]
• Data: RDI Scheme: ₹1 lakh crore over 6 years; ₹20,000 crore in Budget 2025-26 [5]; ₹1,000 crore each sanctioned to TDB and BIRAC, ₹500 crore paid to TDB by March 2026 [6]
• Report/Committee: WHO, Ethics and Governance of Artificial Intelligence for Health (2021): no full international guidance on AI in health; transparency, accountability and equity are core principles [9]
• Law/Case: Technology Development Board Act, 1995 [4]; New Drugs and Clinical Trials Rules, 2019 (the CDSCO rules for IND filings and trials)
• Comparison: In China, Japan, Korea and the USA, companies pay for more than 70% of national R&D; in India they pay for about 36% [8]
• Scheme: RDI Scheme: loans and equity only, no grants, projects at TRL-4 and above, money passed through second-level fund managers [5][6]

15. Mains Relevance

• GS-III: Science & Technology (developments and applications in everyday life; awareness in IT, biotechnology and IPR; indigenisation of technology). Also Indian Economy (mobilisation of resources, investment models).
• GS-II: Health (government policies and interventions; issues relating to health services).
• Possible questions: 1. "AI can shorten drug-discovery timelines, but the bench-to-clinic gap remains India's real bottleneck." Discuss, with reference to recent state-backed financing of AI-led drug development. 2. Examine the role of hybrid financing instruments such as Optionally Convertible Debt under the RDI Scheme in drawing private investment into high-risk R&D. 3. Weigh the opportunities against the regulatory and ethical problems of using AI in drug discovery, with particular reference to rare and neglected diseases in India.

16. Related Topics to Study Next

• RDI Scheme and Anusandhan National Research Foundation (ANRF): the parent framework for the RDI Fund.
• TDB Act, 1995 and the R&D cess: TDB's legal and fiscal basis.
• BIRAC (under DBT): the parallel biotech-startup financier; aspirants often mix it up with TDB.
• New Drugs and Clinical Trials Rules, 2019 / CDSCO: the regulator for IND and clinical-trial approvals.
• National Policy for Rare Diseases, 2021: relevant because DMD and neuromuscular disorders are among the targets.
• IndiaAI Mission: the government's broader AI capacity building.
• PRIP scheme (Promotion of Research & Innovation in Pharma MedTech): the Department of Pharmaceuticals' pharma R&D push.
• BioE3 Policy: the biotech-manufacturing policy that overlaps with biopharma.

17. NCERT Concepts to Revise

• Technology (Economy): The note centres on funding technology maturity from TRL-4 to TRL-6; this explains what technology means as an economic input.
• Statutory body (Polity): TDB is a statutory body created by the TDB Act, 1995; this explains what that status means.
• Collateral (Economy): Banks demand collateral that young AI-drug firms lack, which is why the state steps in with RDI funding.
• Equity share (Economy): OCD can convert into equity, giving the state a stake in the firm's upside.
• Intellectual property rights (Economy): The note raises who owns the IP of publicly co-funded drug candidates, and how access is shared.
• Private sector (Economy): India's weak private-sector R&D spending, about 36% of the total, is the core reason for this state support.

18. Common Errors / Trap Areas

• Wrong ministry or department: TDB comes under DST, Ministry of Science & Technology. It is not under DBT, the Department of Pharmaceuticals or MeitY. [1][3]
• ₹86 crore vs ₹172 crore: ₹86 crore is the TDB/RDI support; ₹172 crore is the total project cost. [1]
• Wrong instrument: the support is Optionally Convertible Debt, not a grant, not pure equity and not a soft loan. [1]
• TRL range: the project moves from TRL-4 to TRL-6 (preclinical up to clinical readiness). It does not cover TRL-1→9 or full clinical trials. [1]
• Confusing the funds: the RDI Fund (₹1 lakh crore scheme, 2025) is separate from TDB's own Fund for Technology Development and Application (TDB Act, 1995). [2][4]